Home / Stocks / APRE

APRE insider trading

Aprea Therapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
13
Bought · 24 mo
$237k
Buys · last 90 days
0 · $0
Most recent buy
2026-02-02

Cluster buy detected

4 insiders bought APRE within a short window (2024-10-10→2024-10-23), $166k in total — cluster score 69/100. Members see the buyers, the score breakdown and the chart.

See the cluster

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-02-02Gilad Oren
President/CEO
Bought28,100$0.89$25k
2026-02-02Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Bought5,700$0.89$5k
2025-12-11Duey Marc
Director
Bought21,459$1.17$25k
2025-12-11Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Bought5,000$1.17$6k
2025-04-04Gilad Oren
President/CEO
Bought5,500$1.84$10k
2024-10-24Gilad Orencluster
President/CEO
Bought500$3.92$2k
2024-10-17Duey Marccluster
Director
Bought30,000$4.39$132k
2024-10-16Hamill John P.cluster
SrVP/CFO/Prin Fin & Acct Ofcr
Bought50$2.46$123
2024-10-16Duey Marccluster
Director
Bought190$2.58$490
2024-10-16Gilad Orencluster
President/CEO
Bought250$2.90$725
2024-10-15Gilad Orencluster
President/CEO
Bought1,150$2.58$3k
2024-10-15Hamill John P.cluster
SrVP/CFO/Prin Fin & Acct Ofcr
Bought450$2.61$1k
2024-10-15Seizinger Bernd R.cluster
Director
Bought10,000$2.68$27k

Most active insider buyers

InsiderRoleBuysTotal bought
Duey MarcDirector3$157k
Gilad OrenPresident/CEO5$41k
Seizinger Bernd R.Director1$27k
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr4$12k

See APRE on the chart

Every insider buy and sell for APRE plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.